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ABSTRACT
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with poor 
prognosis. Cancer cells are characterized by a speciic redox environment that adjusts 
metabolism to its speciic needs and allows the tumor to grow and metastasize. As 
a consequence, cancer cells and especially GBM cells suフer from elevated oxidative 
pressure which requires antioxidant-defense and other sanitation enzymes to be 
upregulated. MTH1, which degrades oxidized nucleotides, is one of these defense 
enzymes and represents a promising cancer target. We found MTH1 expression 
levels elevated and correlated with GBM aggressiveness and discovered that siRNA 
knock-down or inhibition of MTH1 with small molecules eブciently reduced viability 
of patient-derived GBM cultures. The eフect of MTH1 loss on GBM viability was likely 
mediated through incorporation of oxidized nucleotides and subsequent DNA damage. 
We revealed that MTH1 inhibition targets GBM independent of aggressiveness as well 
as potently kills putative GBM stem cells in vitro. We used an orthotopic zebraish 
model to conirm our results in vivo and light-sheet microscopy to follow the eフect 
of MTH1 inhibition in GBM in real time. 
In conclusion, MTH1 represents a promising target for GBM therapy and MTH1 
inhibitors may also be eフective in patients that suフer from recurring disease.
INTRODUCTION
Malignant glioblastoma multiforme (GBM) 
represents the most prevalent form of brain tumors 
and despite the combinatory treatment with radiation 
with Temozolomide, the prognosis of glioma patients 
is dismissive as inherent or acquired resistance lead 
almost inevitably to tumor recurrence and patient death 
within barely 15 months. The current consensus is that 
the recurring tumor develops from treatment-resistant 
GBM stem cells (GSC) [1], and since radiotherapy could 
not be substantially improved in the last years, novel 
chemotherapeutic agents that are also targeting GSCs are 
of urgent need [2]. 
Cancer cells are characterized by a speciic redox 
environment that adjusts the oncogenic metabolism to 
meet the speciic demands of the tumor cell, and allows 
the cancer to grow and metastasize [3]. The cancer redox 
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environment is, however, accompanied by a high-oxidative 
burden that requires upregulation of antioxidant enzymes 
and other non-oncogenic addiction enzymes [4]. It has 
been reported that the free nucleotide pool is especially 
prone to oxidative damage [5], which in consequence 
could lead to nucleotide mispairing, mutations and cell 
death [6] [7]. Among the nucleotides, dGTP is most 
prevalently oxidized and the product, 8-oxo-dGTP, can 
induce mutagenic transversions. There is a large body 
of evidence that the human mutT homologue (MTH1), 
which hydrolyzes 8-oxo-dGTP, represents an essential 
non-oncogenic addition enzyme [8][9], and we and others 
have shown that MTH1 is a potent anti-cancer target [10]
[11]. Moreover, our group has developed speciic small 
molecule inhibitors including TH588 [10] and TH1579 
[12] that target MTH1 and possess promising anti-cancer 
activity in vitro and in vivo [10]. Besides representing 
a general phenomenon in cancer cells, high oxidative 
pressure has also been reported in brain cancers including 
GBM [13-15]. Since recent data from others and our lab 
underlines the important link between the cellular redox 
environment and dependency of functional MTH1 [16, 
17], we sought to investigate if the oxidative pressure of 
GBM cells renders them vulnerable to MTH1 inhibitors. 
RESULTS
MTH1 is upregulated in Glioblastoma multiforme
In order to determine if targeting MTH1 could be a 
novel strategy to treat GBM, we analyzed available cancer 
datasets for a potential connection of MTH1 and brain 
cancer. The TCGA [18, 19], the REMBRANDT [20] and 
Gravendeel [21] data collections all provided consistent 
evidence that MTH1 mRNA expression was higher in 
GBM compared to non-tumor brain tissue and low grade 
GBM (WHO grade II and III; Figure 1, Supplementary 
Figure S1). Due to that signiicant correlation, we 
investigated the e悲ect of our previously characterized 
MTH1 inhibitor TH588 [10] and its pharmacologically 
improved version TH1579 [12] on the survival of six 
di悲erent GBM cell lines. The model compound TH588 
decreased potently the viability of ive GBM lines after 
three days of treatment (IC50 < 5.5 µM), only U87-MG 
required a 5-day treatment for e扉cient targeting (see 
Figure 1, Supplementary Figure S2). Interestingly, the 
levels of MTH1 were lowest in that GBM cell line (see 
Supplementary Figure S2). Our improved MTH1 inhibitor 
TH1579, however, signiicantly decreased viability of all 
GBM lines after a 3-day treatment with an IC50 < 0.4 µM 
(Figure 1, Supplementary Figure S2). 
MTH1 requirement is irrespective of GBM 
aggressiveness
Based on these initial indings, we continued 
assessing the requirement of functional MTH1 for GBM 
cell viability in a panel of seven previously characterized 
GBM lines that can be subdivided in type A and type B, 
depending on their tumorigenic activity and ability to form 
spheres in vitro [22, 23]. We exposed these patient-derived 
GBM lines to our MTH1 inhibitors TH588 and TH1579 
and observed that the inhibition of MTH1 by either 
compound signiicantly decreased viability of all GBM 
cultures, the improved MTH1 inhibitor TH1579 being 
more potent compared to the parental compound TH588 
(Figure 2A, 2B, Supplementary Figure S3). Calculation 
of the individual IC50 values revealed that both MTH1 
inhibitors killed GBM e扉ciently independent of their 
intrinsic aggressiveness (Supplementary Figure S3). Based 
on the previous characterization of the GBM cultures [22, 
23] and their expression level of the GSC surface marker 
CD133 (Supplementary Figure S6), we chose two GBM 
cell cultures with either high, type A: culture #18, or 
low capacity to form neurospheres, type B: culture #7, 
respectively, for a deeper analysis. We conirmed the 
requirement of MTH1 for GBM growth and survival by 
siRNA knock-down (26.5 ± 6.0 % viability compared 
to control in culture #7, p < 0.0001
;
 and 23.7 ± 5.7 % 
viability compared to control in culture #18, p<0.0001), 
and further reassured the observed phenotype by using 
additional three siRNA sequences (see Supplementary 
Table T3 and Supplementary Figure S4). Moreover, 
performing clonogenic assays with GBM culture #18 
showed that not only inhibition of MTH1 using TH588 
and TH1579 signiicantly reduced the number of colonies, 
but also that knock-down of MTH1 by siRNA #1 lead to 
fewer and smaller colonies (Figure 2C, Supplementary 
Figure S4). We determined additionally the target 
engagement of MTH1 by TH1579 in intact GBM#18 
cells and found it to correspond well to the reduction of 
viability (Supplementary Figure S4).
We continued investigating the e悲ects of TH588 
and TH1579 on the cell cycle of GBM cultures 7 
and #18. Exposing these GBM cultures to the MTH1 
inhibitors for 24 hours depleted both the S and G0/G1 
population whereas the fraction of G2/M and polyploid 
cells increased, most prominently in culture 7 and with 
the more potent MTH1 inhibitor TH1579 (Figure 2D, 
2E). Next, we investigated if MTH1 inhibitors are more 
potent than todays standard treatment Temozolomide and 
Palbociclib, AG-120, Ganciclovir, and Dovitinib which 
are currently in clinical trial. Indeed, our improved MTH1 
inhibitor TH1579 was most potent compared to all other 
monotherapies in GBM culture #18 (Figure 3)
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Figure 1: MTH1 is overexpressed in GBM. MTH1 mRNA is upregulated in GBM (n = 528) compared to non-tumor (NT) samples 
(n = 10), and high levels of MTH1 correlate with its gene copy number in GBM (TCGA dataset). Tukey’s Honest Signiicant Di悲erence: 
***p < 0.001 A. Inhibition of MTH1 by the small molecule inhibitors TH588 and TH1579 decreased viability of glioblastoma cell lines B. 
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Incorporation of oxidized dNTPs into DNA after 
MTH1 inhibition
We have previously shown that the loss of functional 
MTH1 leads to incorporation of oxidized nucleotides, 
induces DNA damage and subsequently causes cancer 
cell death [10]. Here, we describe the same phenomenon 
in GBM culture #7 and #18. As determined by comet 
assay (Figure 4C, 4D), the inhibition of MTH1 causes 
incorporation of 8-oxo-dGTP into the DNA of both 
GBM culture 24 hours after exposure. Moreover, MTH1 
inhibition induces DNA damage in both culture #7 and #18 
as exempliied by the average number of yH2AX foci per 
cell which appear after 24 hours of treatment with MTH1 
inhibitors (Figure 4A, 4B and Supplementary Figure S5). 
MTH1 inhibition targets CD133+ GBM stem cells 
in vitro and in vivo
The presence and number of GBM stem cells 
(GSCs) is one of the major factors which determine 
aggressiveness and treatment resistance of the tumor bulk, 
Figure 2: MTH1 inhibitors TH588 and TH1579 target GMB cells independent of aggressiveness. The MTH1 inhibitors 
TH588 and TH1579 target seven patient-derived GBM cultures independent of aggressiveness (type B being more aggressive than type 
A) A. Dose-response curve for TH588 and TH1579 in the most aggressive (#18) and least aggressive (#7) GBM culture B. Clonogenic 
survival of GBM#18 exposed to TH588 and TH1579 C. E悲ect of TH588 and TH1579 on the cell cycle of GBM culture #7 and #18 after 
24 hours of exposure D., E. 
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and surface expression of CD133 (PROM1) is regarded as 
a putative marker for GSCs [24]. In order to elucidate if 
MTH1 inhibition targets both CD133 positive and negative 
cells, we subjected culture #18 to both TH588 and TH1579 
before analysis using low cytometry. After 48 hours of 
treatment we observed that, albeit an overall decreasing 
cell count, the proportion of CD133+ and CD133- cells 
remained stable during the course of the treatment, which 
indicated that MTH1 inhibitors target CD133+ and CD133- 
cells equally well (Figure 5A, Supplementary Figure 
S9B). Importantly, we observed no signiicant decrease of 
the CD133+ population during the experimental timeframe 
in untreated cells, hence can exclude spontaneous 
di悲erentiation of putative GSCs (Supplementary Figure 
S9D). To provide further evidence that MTH1 inhibitors 
target GSCs, we enriched a CD133+ cell population from 
culture #18 by magnetic-activated cell sorting (MACS) to 
about 79 % (Supplementary Figure S9A, B) and exposed 
it to MTH1 inhibitors. After 72 hours of treatment, we 
observed that MTH1 inhibitors targeted the fraction of 
putative GSCs equally well compared to the CD133- cell 
population (IC50TH588 = 12.1 ± 2.9µM and IC50TH1579 = 
0.93 ± 0.79 µM for the CD133+ fraction; IC50TH588 = 12.1 
± 2.7 µM and IC50TH1579 = 1.1 ± 1.0 µM for the CD133- 
fraction; see Figure 5B). Besides measuring viability, we 
also determined the clonogenic survival of the CD133+ 
population upon TH588 and TH1579 treatment, and found 
it to be severely impaired by the loss of functional MTH1 
(Figure 5D, 5E). FACS analysis veriied that the CD133+ 
population did not di悲erentiate during the course of the 
experiment (Supplementary Figure S4B). The expression 
of the transcription factor SOX2 has been associated 
with GBM aggressiveness and GSCs [23, 25]. Based 
on a previously characterized construct [26], we stably 
transfected GBM culture #18, which expresses GFP under 
the SOX2 promoter. Live cell imaging of this GBM culture 
revealed a signiicantly prolonged mitosis of SOX2-GFP+ 
cells upon exposure to TH588 and TH1579 (Figure 5F, 
5G), adding further evidence that MTH1 inhibition targets 
GSCs. Furthermore, we have analyzed the e悲ect of TH588 
and TH1579 on the cell cycle of the CD133+ population of 
GBM #18 and found the sub-G1 population to signiicantly 
increase after exposing to MTH1 inhibitors for 72 hours 
(Figure 5C, Supplementary Figure S10). Lastly, we were 
able to reveal that incorporation of 8-oxo-dGTP into the 
CD133+ population of GBM #18 signiicantly increases 
upon MTH1 inhibition (Figure 5H, 5I). 
The zebraish is a powerful pre-clinical animal 
model and its relevance for glioblastoma research is well 
documented [27, 28]. We generated luciferase expressing 
GBM#18 cells (#18-CMV-LUC), enriched the CD133+ 
putative stem cell population to >85 % (Supplementary 
Figure S11) and transplanted those orthotopically into the 
brain of zebraish embryos. After 5 days of treatment, we 
determined the tumor size by luminescence measurements 
in single embryos and found that treatment with 50 µM 
TH1579 (n = 43) resulted in 26.4 % smaller tumors 
compared to DMSO controls (n = 31; p = 0.011; Fig 
ure 6A, 6B). One prominent advantage of the zebraish 
model is its transparency which allows assessing tumor 
growth and the e悲ect of anti-cancer compounds in vivo 
and real time. We therefore transplanted the GBM line 
U343-MGA:GFP orthotopically into zebraish embryos, 
exposed to 50 µM TH1579 and followed the tumor for 48 
hours intracranially using light-sheet microscopy. In this 
in vivo setting we were not only able to detect numerous 
cells undergoing cell death, but also that the overall tumor 
volume decreased by ~25 % within 35 hours of treatment 
while the non-treated tumor increased its volume by ~ 20 
% (Figure 6C, movie S1). Moreover, we conirmed our 
data in cell culture as we could verify that exposure to 50 
µM TH1579 lead to an increased expression of cleaved 
Figure 3: Inhibition of MTH1 is more potent in GBM than standard treatment. Dose-response curves for the MTH1 inhibitors 
TH588 and TH1579 as well as Temozolomide, AG-120, Palbocilib, Dovitinib and Ganciclovir in the GBM line #18. 
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Figure 4: Inhibition of MTH1 induces DNA damage in GBM cells. Inhibition of MTH1 by TH588 and TH1579 leads to an 
increase of yH2AX foci in GBM line #7 and #18 cells after 24 hours A. Quantiication of yH2AX foci B. Comet assay reveals incorporation 
of 8-oxo-dGTP into DNA of GBM #7 and #18 upon treatment with MTH1 inhibitors for 24 hours C. Quantiication of 8-oxo-dGTP 
incorporation, signiicance calculated with 1-way ANOVA test D. 
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Figure 5: Inhibition of MTH1 targets GBM stem cells. Inhibition of MTH1 with TH588 and TH1579 decreases both the CD133+ 
and CD133- cell population of GBM culture #18 equally well A. Inhibition of MTH1 by TH588 and TH1579 impairs viability of CD133+ 
and CD133- cells equally well B. Exposure to MTH1 inhibitors for 72 hours increases the sub-G1 population of the CD133+ cell population 
of GBM culture #18 C. Clonogenic survival of CD133+ cells exposed to TH588 D. and TH1579 E. Mitosis of SOX2-GFP+ cells is 
signiicantly prolonged upon inhibition of MTH1 F. Quantiication of mitosis duration G. Comet assay reveals incorporation of 8-oxo-
dGTP into DNA of the CD133+ cell population of GBM culture #18 H. Quantiication of comet assay I. 
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caspase 3 as well as the DNA damage marker y-H2AX 
in orthotopically transplanted tumors compared to DMSO 
controls (Figure 6E). 
DISCUSSION
Current therapeutic options for neurological 
cancers including GBM are very limited and lethal tumor 
recurrence is unavoidable. It has been suggested that 
ampliication of chromosome 7 together with loss of chr10 
are very early genetic events GBM ontogeny, potentially 
because of the tumor driver PDGFA on chromosome 7 
[29, 30]. Interestingly, the MTH1-gene is also localized 
on chr7 (7p22) and indeed, by analyzing three di悲erent 
datasets, we found MTH1 transcripts to be signiicantly 
overexpressed in GBM as well as its expression levels to 
be correlated to GBM aggressiveness and proliferative 
potential, a inding that was recently described [31]. 
Besides, there is also direct immunohistological evidence 
that MTH1 protein levels are elevated in human brain 
tumors with highest levels found in aggressive GBM [13]. 
Based on these observations, we thought to investigate 
if GBM growth and survival depends on the presence of 
functional MTH1 protein. 
We performed our initial investigations in a 
collection of seven patient-derived GBM cultures that 
have been previously characterized [22, 23]. Applying 
four di悲erent siRNAs as well as two di悲erent in-house 
developed MTH1 inhibitors, we observed that suppression 
as well as inhibition of MTH1 e扉ciently killed all 
analyzed patient-derived GBM cultures, irrespectively 
of their aggressiveness. Furthermore, we found the target 
Figure 6: MTH1 inhibitors target GBM and GBM stem cells in vivo. GBM #18-CMV-LUC cell enriched for the CD133+ 
population have been orthotopically injected into zebraish embryos. 6 days post injection, embryos exposed to 50 µM TH1579 displayed 
smaller tumors A. Quantiication by luminescence measurements in single embryos showed 26.4 % smaller tumors in TH1579 treated 
embryos (n = 43) compared to DMSO controls (n = 31; p = 0.011) B. Still images of real-time light sheet microscopy on orthotopic 
xenotransplants exposed to 50 µM TH1579 apoptotic cells encircled C. Determination of tumor volume of xenotransplant. Grey circle: 
DMSO control, black circle TH1579 treated (tumor shown in (C). The asterisks mark the time-point when the transplants started leaving 
the focal plane D. Immunocytochemistry on cleaved caspase as well as y-H2AX in orthotopic xenotransplants treated for 5 days with 50 
µM TH1579 or DMSO E.
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engagement of TH1579 for MTH1 in intact GBM#18 
cells closely corresponding to the e悲ect on cell viability, 
indicating speciicity of the compound. During preparation 
of this manuscript two other groups independently 
conirmed our indings that MTH1 is indispensable for 
GBM growth and survival [31, 32]. Spurred by these 
initial results, we continued with an in-depth analysis of 
our most aggressive GBM cell culture #18 and the least 
aggressive representative culture #7. 
Cancer cells and GBM cells in particular su悲er 
from a high redox pressure and are therefore dependent on 
speciic detoxiication enzymes including MTH1, which 
degrades oxidized nucleotides including 8-oxo-dGTP. 
Indeed, after we inhibited MTH1 with either TH588 or 
TH1579, we were able to detect speciic 8-oxo-guanine 
lesions in the DNA of the analyzed GBM cultures using 
a modiied comet assay. As anticipated, we also observed 
an increase of general DNA damage following exposure 
to MTH1 inhibitors, most likely due to the incorporation 
of 8-oxo-dGTP, which is known to eventually lead to 
cellular senescence through persistent DDR signaling [33]. 
Since it has recently been published that DNA synthesis 
can occur at common fragile sites (CFSs) during mitosis 
of cells su悲ering from replicative stress, i.e. cancer cells 
[34], it will be interesting to investigate if 8-oxo-dGTP 
might be incorporated into these fragile sites in absence 
of functional MTH1 with fatal consequences. Besides 
its DNA damaging potential, it has been published that 
modiied guanine nucleotides including modiications on 
the 8th position may a悲ect the polymerization of tubulin 
in vitro and in vivo [35, 36]. Since we have observed 
that our MTH1 inhibitors induce a G2/M arrest as well 
as lead to polyploid cells, we are currently exploring if 
these e悲ects are based on the 8-oxo-dGTP interference 
with tubulin dynamics. The vast majority of GBM 
reappears after initial treatment, most often due to 
overexpression of O6-methyl-guanidine methyltransferase 
(MGMT) which confers resistance to Temozolomide [1]. 
Importantly, despite expressing very high levels of MGMT 
(see Supplementary Figure S7) and being resistant to 
Temozolomide, we show that MTH1 inhibitors e扉ciently 
target GBM cultures #7 and #18. Since MTH1 inhibitors 
potently decreased viability of these resistant cultures, it 
is tempting to speculate that MTH1 inhibition could be 
used as novel strategy to target recurring, Temozolomide 
resistant GBMs.
Although the cancer stem cell hypothesis remains 
controversial, there is a large body of evidence supporting 
a hierarchical architecture of GBM with GSCs at the 
apex [37, 38]. GSCs drive aggressiveness of the tumor, 
confer resistance to current treatments and are the main 
cause for disease recurrence [1]. Since we found that our 
MTH1 inhibitors target the two di悲erent GBM cultures 
potently and independent of their aggressiveness, we 
investigated if GSCs are also dependent on functional 
MTH1. The surface protein CD133 is currently one of 
the best available markers for putative GSCs [24], thus 
we fractionized culture #18 with MACS accordingly and 
present several lines of evidence that MTH1 inhibitors 
decrease survival of the CD133 enriched and depleted 
fraction of GBM culture #18 equally well. Moreover, our 
inhibitors induced a dramatic prolongation of mitosis as 
well as lead to incorporation of 8-oxo-dGTP into the DNA 
of culture #18 cells expressing SOX2, a stemness marker 
also upregulated in GSCs [23, 25]. We transplanted the 
CD133+ enriched fraction intracranially into zebraish 
embryos, which is a clinically relevant and ethically sound 
model for GBM [27, 28]. By that, we were not only able 
to conirm the ability of MTH1 inhibitors to target GSCs 
in vivo, but also to monitor in vivo and in real time how 
GSC cells died due to this anti-cancer drug. Although the 
transplanted zebraish embryos were freely swimming in 
a 50 µM solution of TH1579, the actual drug exposure 
of the tumor was likely signiicantly lower due to limited 
uptake of this small molecule into the zebraish. However, 
we recently conirmed good pharmacokinetic parameters 
including good oral availability in mouse [12]. As the 
cellular fraction depleted for CD133 did not form stable 
intracranial tumors, likely due to the absence of stem cells, 
we followed additionally a non-orthotopic implantation 
approach to show that inhibition of MTH1 targets both 
GBM as well as GSCs (see Supplementary Figure S12). 
It is well established that GSCs preferentially localize in 
the perinecrotic hypoxic area [39, 40], which contributes 
to regulate their tumorigenic capacity [41]. Hypoxia 
in general and the perinecrotic region speciically are 
associated with oxidative stress [42-44], and GSCs were 
indeed described to su悲er from higher oxidative pressure 
compared to non-GSCs [45]. We have recently found 
that hypoxia and the tumor redox environment determine 
sensitivity to MTH1 inhibition [16], therefore the elevated 
redox pressure present in GSCs might explain their 
addiction to functional MTH1. 
In summary, we have presented evidence that 
inhibition of MTH1 might represent an e扉cient strategy 
to target GBM. 
MATERIALS AND METHODS
Data analysis
GBM expression data were analyzed through 
the GlioVis data portal (http://gliovis.bioinfo.cnio.es) 
(M. Squatrito, manuscript in preparation). Multiple 
comparisons were performed by ANOVA test followed by 
Tukey’s Honest Signiicant Di悲erence post-hoc analysis.
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Antibodies and chemicals
The following antibodies were used: mouse anti-
yH2AX (Millipore), mouse anti beta-actin (Abcam) and 
IRDye 680RD donkey anti-mouse (LI-COR), rabbit 
anti-cleaved caspase 3 (Abcam), mouse anti y-H2AX 
(Millipore), anti-rabbit/555 (Invitrogen) and anti-
mouse/488 (Life technologies). Chemicals were purchased 
from Sigma-Aldrich. MTH1 inhibitors were synthesized 
in-house and dissolved in DMSO to 10 mM [10, 12].
Cell culture, comet and viability assay
All cell lines used have been obtained from 
ATCC during the last four years; regular mycoplasma 
tests have been performed. Generation, authentication 
and propagation of patient-derived GBM cell cultures 
have been described elsewhere [23]. Cell viability 
measurements using the MTT or resazurin assay were 
performed as described [10]. The modiied comet assay 
has been described in detail before [10]. Briely, the 
8oxodGTP speciic exonuclease Ogg1 has been used to 
induce DNA strand breaks at 8-oxo-dGTP positions which 
could then speciically be detected using the comet assay. 
The SOX2-GFP reporter cells have been established with 
a lentivirus based system following standard protocols and 
using a previously described construct [26]. Lipofectamine 
was used for siRNA knock-downs. SiRNA sequences see 
table S2 and Supplementary Figure S7. For clonogenic 
assays using MTH1 inhibitors, 500 cells were seeded in 10 
cm dishes and treated as speciied. After 10 days, colonies 
were stained with methylene blue and counted manually. 
Neither medium nor treatment was exchanged during the 
course of the experiment. For clonogenic assays using 
siRNA, cells were treated with siRNA for 24 hours before 
seeding, then propagated and stained as above. Colony 
number and size was determined using the cell proiler 
software. 
CETSA- Alpha-screen
Glioma#18 cells were grown in 6-well plates and 
treated with TH1579 at di悲erent concentrations for 1 
hour at 37 °C. After trypsinization cells were collected 
by centrifugation and resuspended in 50 µl of TBS, pH 
8.0, and protease inhibitor COMPLETE (Roche). Cell 
suspensions were transferred to a 96-well PCR plate 
(Agilent) and heated to 58 °C followed by addition of 
lysis bu悲er (SureFire Ultra5x, Perkin Elmer). After 20 
minutes lysis at room temperature lysates were transferred 
to an assay plate (Proxiplate, Perkin Elmer) and the 
amounts of stabilized MTH1 were analyzed using Alpha 
Lisa immunoassay[46]. Cell lysates were incubated with 
two MTH1 antibodies diluted in immuno assay bu悲er 
(Perkin Elmer), mouse anti-MTH1 (Ls-c197715, LS-
Bio), 1:20000 and rabbit anti-MTH1 (polyclonal, in house 
produced), 1:2000, for two hours at room temperature. 
Anti-mouse IgG alpha donor beads 10 µg/ml and anti-
rabbit IgG acceptor beads, 10 µg/ml (Perkin Elmer) were 
added to the assay plate followed by incubation at room 
temperature overnight. Plates were read using Envision 
plate reader (Perkin Elmer), the light emission was directly 
proportional to the amount of stabilized MTH1
Magnetic-activated cell sorting
Cells were harvested with Accutase (Sigma) 
and resuspended in PBS containing 0.5 % BSA and 2 
mM EDTA. Sorting was performed using the CD133 
MicroBead Kit , e扉ciency of cell sorting was analyzed by 
low cytometry using the Labeling Check Reagent-PE (all 
Miltenyi Biotec). 
Flow cytometry 
Harvested cells were resuspended in PBS 
containing 2 % FBS and labelled with anti-CD133/1-APC 
(Miltenyi Biotec) in presence of human Fc-Block (BD 
Biosciences). The mouse IgG1 isotype control antibody 
conjugated to APC (Milteny Biotec) served as control (see 
Supplementary Figure S6). For cell cycle analysis, cells 
were pulsed for 4 h (culture #7) or 0.5 h (culture #18) 
with 10 µM EdU followed by ixation and incubation with 
mouse anti-yH2AX overnight. EdU was detected based on 
a Click-iT EdU system, DNA was stained using Hoechst 
33342 according to standard protocols. 
RNA isolation, reverse transcription and 
quantitative real-time PCR
RNA was isolated and cDNA was synthesized with 
the Maxima First strand cDNA Synthesis Kit and RTqPCR 
was run using the Luminaris Color HiGreen qPCR Master 
Mix (all ThermoScientiic) on a Rotorgene (Qiagen). 
Relative gene expression levels normalized to beta actin 
were calculated according to the 2-〉〉CT method. Primer 
were purchased pre-veriied (KICqStart, Sigma) and 
always span an exon-intron junction (see table S1). 
Zebraish maintenance, injections and exposure
Zebraish (TL) were raised and staged according 
to standard protocols. Cells transplanted into zebraish 
were transferred to stem cell medium (Neurobasal 
medium/DMEM/F12 mixture containing B27 and N2 
supplements as well as 10 ng/ml bFGF and 20 ng/ml EFG) 
7 days before injection. Labelling and transplantation 
has been described before [47]. 24 hours after injection, 
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treatment was started. All experiments were performed in 
accordance to the international and local ethical guidelines 
(N207/14).
Generation of luciferase expressing cells and 
luciferase measurement
The glioblastoma line #18 was stably transfected 
with pLenti CMV Puro LUC (Addgene) using routine 
protocols. To measure luminescence, 1 embryo/ well was 
plated in 96 well plates and lysed (10 % glycerol, 1 % 
Triton-X100, 8 mM MgCl2, 1 mM DTT, 25 mM Tris-
phosphate pH7.8) for 20 min followed by addition of 
luciferase detection bu悲er (1 mM DTT; 1 mM ATP, 0.3 
mg/ml luciferin potassium salt, 25 mM Tris-phosphate pH 
7.8) and light detection. 
Live cell imaging
The SOX2-GFP reporter cells were seeded in 96 
well black/clear plates at a concentration of 6000 cells per 
well and subjected to treatment the day after. Within 30 
min after addition of MTH1 inhibitors, live cell imaging 
was performed using the Image Express microscope 
(Molecular Devices) at 37° C in 5 % CO
2
 atmosphere. 
Images were acquired with a 20x lens every 10 min for 24 
hours. The images of each channel were assembled into 
AVI-movies using the MetaXpress software and the cell 
division was analyzed with ImageJ 
Light sheet microscopy
24 hpf embryos were embedded in 1% low melt 
agarose in a glass capillary and extruded into a sample 
chamber containing E3 medium supplemented with 
MS222. Images were acquired using a Light Sheet Z.1 
(Carl Zeiss, Germany) with a water dipping 20X detection 
objective (W-Plan-APOCHROMAT-1.0NA) and dual side 
10X illumination objectives (LSFM, 0.2NA). Samples 
were illuminated from a single side and Z-stacks were 
acquired every 15 min using a 1.2X optical zoom, 4.13 
µm light sheet thickness and 2 µm Z-interval. Tumor 
volume was measured using the Countour Surface tool in 
Imaris 8.3.1 (Bitplane). For visualization, max intensity 
projections were produced and drift was corrected using a 
rigid body transformation in the ImageJ plugin, StackReg 
[48]
Immunocytochemistry
Cells were seeded in 6 well plates and subjected to 
treatment 24 hours after. After exposure, cells were treated 
for immunocytochemistry according to standard protocols. 
Embryos were prepared for cryo-sections as described 
previously [49] and sections were stained using routine 
protocols.
Documentation and statistical analysis
Pictures were taken with a Leica LSM 780 confocal 
microscope or a Leica MZ16 microscope equipped 
with a Leica DCF3000FX camera. Image data was 
processed with GIMP or ImageJ without obstructing any 
original data. Experiments have been performed at least 
in triplicates, the results are expressed as mean ± SD. 
Statistical signiicance was determined using the two-
tailed students t-test unless otherwise stated with the 
following p values considered signiicant: *: p <0.05; **: 
p <0.001; ***: p < 0.0001.
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